FDA grants accelerated approval to telisotuzumab vedotin-tllv for NSCLC with high c-Met protein overexpression

Drug

Emrelis (telisotuzumab vedotin-tllv) · Anti-c-Met antibody-drug conjugate

Condition

Thoracic